First Pregnancies Reported Using Cell Robotics' In Vitro Fertilization Workstation.

ALBUQUERQUE, N.M.--(BW HealthWire)--May 5, 1998--Cell Robotics International, Inc. (OTC: CRII) announced today that two pregnancies have occurred as a result of the company's clinical trial of its proprietary In Vitro Fertilization (IVF) Workstation.

These pregnancies are significant not only because they occurred in previously infertile women, but also because these women are representative of a growing population of women who turn to and are seeking more successful assisted reproduction technology to achieve pregnancy. More and more couples are delaying parenthood, or are choosing to freeze their embryos for later implantation. The company's new assisted reproduction technology is offering assistance to women and couples who previously were unsuccessful at achieving pregnancy.

The instrument that was used to help these women become pregnant, the IVF Workstation, is being tested in an FDA-approved clinical trial at prominent sites in Belgium, Australia, Israel and in the United States. The computer-controlled instrument not only enhances the diagnosis of eggs and embryos before they are chosen for fertilization or implantation into the mother, but also incorporates advanced tools and procedures for the IVF laboratory.

One of the newest and most exciting tools introduced by the IVF Workstation is laser-assisted hatching. This method uses a laser beam to thin the shell of an embryo so that it will be more likely to hatch once it has been placed into the mother's womb. As women enter their late thirties and forties, the shell or zona pellucida around the egg often becomes tough. It is thought that assisted hatching improves the embryo's chances of hatching and developing into a healthy fetus.

At a well-known IVF clinic in Australia, four patients, using frozen embryos, were chosen to be the first participants in the clinical trial. In this randomized study, one patient's embryos received the laser assisted hatching treatment and three were assigned to a control group with no hatching. The one patient who received laser assisted hatching became pregnant. None of the three women in the control group (no laser assisted hatching) became pregnant.

In the United States, at a highly respected IVF clinic, four patients with frozen embryos (all over 39 years of age and previously unsuccessful with classical IVF attempts) received the laser assisted hatching treatment. One of the four patients whose embryos were treated with laser assisted hatching became pregnant.

IVF is a rapidly growing area of human infertility treatment, with some estimates reporting as many as 100,000 IVF procedures performed each year. The addition of computer control and laser assisting hatching should improve IVF pregnancy success rates. The IVF Workstation has been cleared for sale in Europe and the instrument will be demonstrated June 20-24, 1998 at the European Society of Human Reproduction and Embryology in Sweden.

Cell Robotics International, Inc., manufactures, markets, and distributes scientific and medical laser devices. In addition to the IVF Workstation, these devices include the FDA-cleared Lasette(TM), a laser finger perforator for diabetics to painlessly draw blood for glucose testing, the FDA-cleared RevitaLase(TM), an Erbium:YAG laser for use in dermatological applications, and the Cell Robotics Workstation, a research instrument which incorporates the LaserTweezers(R) and LaserScissors(TM) for manipulating and cutting cells and chromosomes.

More information on Cell Robotics International, Inc. can be found on the company's Web Site at www.cellrobotics.com/cell.

CONTACT: Newport Capital Consultants, Inc.

Gary E. Bryant, 760/360-2326

or

Craig Rogers, 719/590-1793